PLX (STOCKS)
Protalix BioTherapeutics, Inc. Common Stock
$2.860000
-0.060000 (-2.05%)
Prev close: $2.920000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Dror Bashan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $229.20M
- Employees
- 213
- P/E (TTM)
- 42.01
- P/B (TTM)
- 4.43
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
1
Strong Buy
3
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$0.03 | $0.06 | -0.0256 | -46.04% |
|
Jun 2025 (Q2)
|
$0.00 | $0.03 | -0.0303 | -100.00% |
|
Mar 2025 (Q1)
|
$-0.05 | $0.03 | -0.0803 | -265.02% |
|
Dec 2024 (Q4)
|
$0.09 | $0.07 | +0.0193 | +27.30% |
Financial Statements
| Revenues | $61.84M |
| Benefits Costs and Expenses | $55.36M |
| Cost Of Revenue | $26.26M |
| Costs And Expenses | $55.36M |
| Gross Profit | $35.58M |
| Nonoperating Income/Loss | $117.00K |
| Operating Expenses | $29.21M |
| Selling, General, and Administrative Expenses | $11.16M |
| Research and Development | $18.06M |
| Operating Income/Loss | $6.37M |
| Income/Loss From Continuing Operations After Tax | $5.39M |
| Income/Loss From Continuing Operations Before Tax | $6.48M |
| Income Tax Expense/Benefit | $1.09M |
| Income Tax Expense/Benefit, Current | $913.00K |
| Income Tax Expense/Benefit, Deferred | $177.00K |
| Net Income/Loss | $5.39M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $5.39M |
| Net Income/Loss Available To Common Stockholders, Basic | $5.39M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.08 |
| Diluted Earnings Per Share | $0.08 |
| Basic Average Shares | 77,454,719 |
| Diluted Average Shares | 85,981,197 |
| Assets | $82.26M |
| Current Assets | $66.50M |
| Inventory | $21.26M |
| Other Current Assets | $45.25M |
| Noncurrent Assets | $15.76M |
| Fixed Assets | $4.72M |
| Other Non-current Assets | $11.04M |
| Liabilities | $29.36M |
| Current Liabilities | $21.95M |
| Wages | $745.00K |
| Other Current Liabilities | $21.20M |
| Noncurrent Liabilities | $7.41M |
| Equity | $52.91M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $52.91M |
| Liabilities And Equity | $82.26M |
| Net Cash Flow From Operating Activities | -$10.03M |
| Net Cash Flow From Operating Activities, Continuing | -$10.03M |
| Net Cash Flow From Investing Activities | -$16.57M |
| Net Cash Flow From Investing Activities, Continuing | -$16.57M |
| Net Cash Flow From Financing Activities | $12.81M |
| Net Cash Flow From Financing Activities, Continuing | $12.81M |
| Net Cash Flow | -$13.80M |
| Net Cash Flow, Continuing | -$13.80M |
| Comprehensive Income/Loss | $5.39M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $5.39M |
| Other Comprehensive Income/Loss | $0.00 |